Invega (paliperidone) is an antipsychotic medication approved to treat schizophrenia and schizoaffective disorder in adults. It works by adjusting the activity of dopamine and serotonin in the brain, two chemical messengers that play central roles in how we perceive reality, regulate mood, and organize thoughts.
FDA-Approved Uses
Invega carries two primary approvals. The first is for schizophrenia, covering both acute episodes and long-term maintenance. The second is for schizoaffective disorder, a condition that combines psychotic symptoms like hallucinations or delusions with mood episodes such as depression or mania. For schizoaffective disorder, Invega can be used on its own or alongside mood stabilizers and antidepressants.
In schizophrenia, the goal is to reduce positive symptoms (hallucinations, paranoia, disorganized thinking) and help prevent relapses over time. In schizoaffective disorder, it targets those same psychotic symptoms while the mood component is managed either by Invega alone or in combination with other medications.
How Invega Works in the Brain
Paliperidone primarily blocks two types of receptors: dopamine D2 receptors and serotonin 5-HT2A receptors. Brain imaging studies show it occupies roughly 70 to 80 percent of dopamine D2 receptors in key brain regions, which is the range associated with reducing psychotic symptoms without excessive side effects. By also blocking certain serotonin receptors, it helps balance mood and may reduce the movement-related side effects that older antipsychotics are known for.
One notable feature of paliperidone is that it bypasses significant liver processing. Most antipsychotics are broken down extensively by liver enzymes before reaching the bloodstream, which can create problems for people with liver conditions or those taking multiple medications that compete for the same enzymes. Paliperidone sidesteps this issue. It is actually the active form of an older antipsychotic called risperidone, meaning the body doesn’t need to convert it before it starts working. This makes drug interactions involving liver metabolism less of a concern.
Available Formulations
Invega comes in several forms designed around different treatment needs and schedules:
- Invega (oral tablets): Extended-release tablets taken once daily. These are often used when starting treatment or for people who prefer an oral medication.
- Invega Sustenna (monthly injection): A long-acting injection given once a month in a healthcare setting. Patients typically need to be stable on this formulation for at least four months before transitioning to longer-acting options.
- Invega Trinza (3-month injection): Given once every three months. This option is available after a patient has been stable on the monthly injection for at least one full 3-month cycle.
- Invega Hafyera (6-month injection): The longest-acting option, administered just twice a year. The drug begins releasing on day one and maintains detectable levels for more than 18 months after a single dose.
The injectable versions are particularly valuable for people who have difficulty remembering daily pills or who have experienced relapses after stopping oral medication. Each step to a longer-acting injection requires demonstrated stability on the previous formulation, so the transition is gradual.
Off-Label Uses
Some clinicians prescribe Invega for conditions beyond its official approvals, though the evidence base for these uses is thinner. One area of interest is aggression and irritability in people with autism spectrum disorder. In an 8-week open-label trial of 25 participants aged 12 to 21 with autism-related irritability, 84 percent showed meaningful improvement. Individual case reports have described dramatic reductions in aggression and self-injurious behavior in patients who hadn’t responded to multiple other medications. These results are promising but preliminary, as no large, placebo-controlled trials have been completed in this population.
Common Side Effects
Like other antipsychotic medications, Invega can cause side effects that vary in severity. Weight gain is one of the more common concerns, along with drowsiness, restlessness, and elevated levels of prolactin (a hormone that can cause breast tenderness, menstrual changes, or sexual dysfunction). Some people experience metabolic changes, including increases in blood sugar and cholesterol, which is why periodic blood work is a standard part of treatment.
Movement-related side effects, sometimes called extrapyramidal symptoms, can also occur. These include muscle stiffness, tremors, or involuntary movements. They tend to be less common with Invega than with older antipsychotics, but the risk isn’t zero, especially at higher doses.
Important Safety Information
Invega carries a boxed warning, the FDA’s most serious safety alert, regarding use in elderly patients with dementia-related psychosis. Antipsychotic medications as a class are associated with an increased risk of death in this population, and Invega is not approved for treating dementia-related psychosis.
Because paliperidone doesn’t rely heavily on liver metabolism, it may be a better fit for patients with liver impairment compared to medications like risperidone. However, paliperidone is primarily cleared through the kidneys, so kidney function matters. Your prescriber will likely check kidney function before starting treatment and may adjust the dose accordingly.
What to Expect During Treatment
Symptom improvement with antipsychotics generally doesn’t happen overnight. Most people begin to notice some changes within the first one to two weeks, particularly with acute symptoms like agitation or severe paranoia. Fuller improvement in hallucinations, delusions, and disorganized thinking often takes four to six weeks. The injectable formulations maintain steady drug levels between doses, which can help avoid the peaks and valleys that sometimes occur with daily pills.
Treatment with Invega is typically long-term. Schizophrenia and schizoaffective disorder are chronic conditions, and stopping medication, even after feeling well for months or years, carries a significant risk of relapse. The availability of 3-month and 6-month injections reflects this reality, making it easier to stay on treatment with fewer appointments and no daily pill burden.